Clinical Trial Update: The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluated the pharmacokinetics, safety, and tolerability of ZL-2306 (niraparib) in patients with ovarian cancer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• ZL-2306 (niraparib) (niraparib)

Snippet

Sponsor: Zai Lab (Shanghai) Co., Ltd. | Conditions: Ovarian Cancer | Phase 1 | Status: COMPLETED